Text Size

Treatment of Patients With Major Depressive Disorder With MK0869

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00034944
First received: May 2, 2002
Last updated: January 14, 2010
Last verified: January 2010
History of Changes
  Purpose

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.


Condition Intervention Phase
Major Depressive Disorder
 Drug: MK0869, aprepitant
Drug: Comparator: placebo
 Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
Official Title: A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • HAMD-17 total score at week 8. Tolerability.

Secondary Outcome Measures:
  • CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Estimated Enrollment: 450
Study Start Date: January 2002
Detailed Description:

The duration of treatment is 8 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Major depressive disorder

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034944

Locations
United States, Connecticut
Call for information
New Britain, Connecticut, United States, 06050
United States, Florida
Call for information
Altamonte Springs, Florida, United States, 32701
Call for information
Miami, Florida, United States, 33161
United States, Louisiana
Call for information
Shreveport, Louisiana, United States, 71103
United States, Virginia
Call for information
Richmond, Virginia, United States, 23294
United States, Wisconsin
Call for information
Middleton, Wisconsin, United States, 53711-3415
Sponsors and Collaborators
Merck
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00034944     History of Changes
Other Study ID Numbers: 2006_403, Formally-22, MK0869-063
Study First Received: May 2, 2002
Last Updated: January 14, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Aprepitant
Antiemetics
 Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents

ClinicalTrials.gov processed this record on May 19, 2013